Jefferies Financial Group Inc. Sells 369,178 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Jefferies Financial Group Inc. reduced its stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 97.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,158 shares of the medical device company's stock after selling 369,178 shares during the period. Jefferies Financial Group Inc.'s holdings in Tandem Diabetes Care were worth $330,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. AlphaQuest LLC grew its stake in shares of Tandem Diabetes Care by 138.7% in the fourth quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock worth $34,000 after acquiring an additional 541 shares during the last quarter. Jones Financial Companies Lllp grew its stake in shares of Tandem Diabetes Care by 195.8% in the fourth quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company's stock worth $41,000 after acquiring an additional 748 shares during the last quarter. Assetmark Inc. grew its stake in shares of Tandem Diabetes Care by 77.5% in the fourth quarter. Assetmark Inc. now owns 1,225 shares of the medical device company's stock worth $44,000 after acquiring an additional 535 shares during the last quarter. Smartleaf Asset Management LLC raised its holdings in Tandem Diabetes Care by 163.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company's stock worth $65,000 after acquiring an additional 1,101 shares during the last quarter. Finally, Venturi Wealth Management LLC raised its holdings in Tandem Diabetes Care by 5,955.9% in the 4th quarter. Venturi Wealth Management LLC now owns 2,059 shares of the medical device company's stock worth $74,000 after acquiring an additional 2,025 shares during the last quarter.

Analyst Ratings Changes

TNDM has been the subject of a number of recent analyst reports. Sanford C. Bernstein lowered shares of Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and decreased their price objective for the stock from $35.00 to $25.00 in a report on Friday, February 28th. Piper Sandler decreased their price objective on shares of Tandem Diabetes Care from $36.00 to $30.00 and set an "overweight" rating for the company in a report on Thursday, May 1st. Canaccord Genuity Group boosted their price objective on shares of Tandem Diabetes Care from $58.00 to $59.00 and gave the stock a "buy" rating in a report on Thursday, May 1st. Barclays decreased their price objective on shares of Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating for the company in a report on Friday, February 28th. Finally, Wells Fargo & Company decreased their price objective on shares of Tandem Diabetes Care from $22.00 to $20.00 and set an "equal weight" rating for the company in a report on Thursday, May 1st. Eight equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, Tandem Diabetes Care has a consensus rating of "Moderate Buy" and an average target price of $39.81.

Tandem Diabetes Care Stock Performance

TNDM traded down $1.87 during mid-day trading on Wednesday, reaching $21.65. 1,352,285 shares of the company traded hands, compared to its average volume of 1,503,647. Tandem Diabetes Care, Inc. has a 52-week low of $15.75 and a 52-week high of $53.69. The company's fifty day moving average price is $19.31 and its 200-day moving average price is $27.72. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29. The stock has a market capitalization of $1.44 billion, a P/E ratio of -11.22 and a beta of 1.47.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.07). Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The business had revenue of $234.42 million for the quarter, compared to the consensus estimate of $220.19 million. During the same period in the previous year, the firm earned ($0.65) EPS. The company's revenue was up 22.3% on a year-over-year basis. On average, sell-side analysts expect that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current year.

Insider Activity

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos acquired 10,538 shares of the business's stock in a transaction dated Friday, March 7th. The stock was purchased at an average price of $18.12 per share, with a total value of $190,948.56. Following the transaction, the chief operating officer now directly owns 10,538 shares in the company, valued at approximately $190,948.56. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.90% of the company's stock.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.